Regeneron Pharmaceuticals (NASDAQ:REGN) Releases Quarterly Earnings Results, Beats Expectations By $4.13 EPS

Regeneron Pharmaceuticals (NASDAQ:REGN) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13, FiscalAI reports. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. During the same period in the prior year, the business posted $12.81 earnings per share. The company’s revenue was up 16.7% on a year-over-year basis.

Here are the key takeaways from Regeneron Pharmaceuticals’ conference call:

• Strong second-quarter performance: Total revenue rose 17% year over year to $4.3 billion, while non-GAAP EPS increased 11% to $14.29. Dupixent, EYLEA HD, and Libtayo each reached record quarterly sales.
• Dupixent momentum remains robust, with global sales of $6 billion, up 38% at constant exchange rates, supported by growth across existing indications and newer launches. Growth is expected to remain strong, though it will moderate in the second half due to tougher comparisons.
• EYLEA HD is rapidly converting the U.S. franchise: sales increased 52% year over year to $596 million and exceeded legacy EYLEA sales for the first time. Regeneron is pursuing approval of a pre-filled syringe, which management believes could further improve adoption.
• Several pipeline catalysts are approaching, including potential FDA decisions for cemdisiran in generalized myasthenia gravis in November and garetosmab in FOP in August, along with data readouts for the PNH complement program and geographic atrophy program later this year.
• Legacy EYLEA remains under pressure: U.S. sales fell 45% year over year to $412 million as patients converted to EYLEA HD and competition increased. Management expects further low-to-mid-teens sequential demand declines in the second half, partly because of multiple aflibercept biosimilar launches.

Regeneron Pharmaceuticals Price Performance

REGN traded up $42.92 during trading on Thursday, reaching $738.34. The stock had a trading volume of 1,460,610 shares, compared to its average volume of 708,137. The stock has a market cap of $78.06 billion, a PE ratio of 17.99, a PEG ratio of 27.78 and a beta of 0.24. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. Regeneron Pharmaceuticals has a one year low of $541.00 and a one year high of $821.11. The business has a 50-day moving average of $640.66 and a 200-day moving average of $711.35.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be given a $0.94 dividend. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 9.16%.

Analysts Set New Price Targets

Several equities analysts recently commented on REGN shares. Morgan Stanley reduced their price objective on shares of Regeneron Pharmaceuticals from $788.00 to $730.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 8th. Barclays cut their price target on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Wells Fargo & Company lowered their price objective on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating on the stock in a research report on Monday, May 18th. Canaccord Genuity Group reduced their target price on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Finally, Citigroup lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $900.00 to $700.00 in a research note on Monday, May 18th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $787.88.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director owned 17,303 shares of the company’s stock, valued at $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by company insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Compound Planning Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 69.3% in the 4th quarter. Compound Planning Inc. now owns 1,676 shares of the biopharmaceutical company’s stock valued at $1,294,000 after purchasing an additional 686 shares in the last quarter. Birchwood Financial Partners Inc. bought a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $32,000. Corient Private Wealth LLC boosted its position in Regeneron Pharmaceuticals by 32.5% during the fourth quarter. Corient Private Wealth LLC now owns 23,019 shares of the biopharmaceutical company’s stock valued at $17,768,000 after buying an additional 5,647 shares during the period. Alpine Woods Capital Investors LLC purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at about $247,000. Finally, Ameriflex Group Inc. bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $112,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Results exceeded expectations: Regeneron reported second-quarter revenue of $4.29 billion, up 16.7% year over year and above the roughly $3.82 billion consensus estimate. Non-GAAP EPS was $14.29 versus expectations of approximately $10.16, helping drive renewed investor interest. Regeneron Reports Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: Key growth products performed well: Dupixent sales, recorded by partner Sanofi, rose 38% to a record $6.0 billion, while U.S. EYLEA HD sales increased 52% to a record $596 million. Libtayo sales also grew 30% to $489 million, demonstrating strength beyond the company’s legacy EYLEA franchise. Regeneron beats quarterly estimates on eczema drug strength, shares rise
• Positive Sentiment: Pipeline and strategic expansion: Management highlighted its broader development pipeline, while a collaboration with Telix Pharmaceuticals could expand Regeneron’s oncology presence through next-generation radiopharmaceutical therapies. Why Regeneron is up after mixed Q2 results and Telix oncology deal
• Neutral Sentiment: Dividend declared: Regeneron announced a quarterly dividend of $0.94 per share, payable August 31 to shareholders of record August 18. The approximately 0.5% yield provides limited income support but is unlikely to be a major valuation driver.
• Neutral Sentiment: Broader sector weakness: Healthcare stocks declined late in the session, creating a headwind for the group even as Regeneron benefited from its earnings release.
• Negative Sentiment: Fianlimab-Libtayo trial litigation: Multiple law firms publicized a securities class action alleging that Regeneron misrepresented the risks and protocol changes surrounding the failed Phase 3 melanoma trial. The allegations relate to investors who purchased shares from August 1, 2025, through May 15, 2026; the lead-plaintiff deadline is September 14, 2026. The lawsuit follows an earlier, severe market reaction to the trial failure and could add legal costs and reputational risk, although the claims have not been proven. Hagens Berman Regeneron securities class action alert

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.